Creative Planning
NRSN icon

Creative Planning’s NeuroSense Therapeutics NRSN Stock Holding History

Creative Planning’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.21K Sell
11,410
-501
-4% -$391 ﹤0.01% 4234
2026
Q1 		$8.99K Hold
11,911
– – ﹤0.01% 4077
2025
Q4 		$9.16K Buy
+11,911
New +$12.5K ﹤0.01% 3872

Other funds holding NRSN

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Creative Planning's NRSN Position: Q2 2026 in Review

Creative Planning reduced its NeuroSense Therapeutics (NRSN) stake by 4.2% in Q2 2026, selling an estimated $391 and leaving 11,410 shares worth $8.21K. The position accounts for ﹤0.01% of the portfolio, ranked #4234.

Creative Planning first reported a position in NRSN in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.16K in Q4 2025. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

  • Creative Planning held 11,410 shares of NeuroSense Therapeutics worth $8.21K as of Q2 2026.
  • Creative Planning sold 501 NeuroSense Therapeutics shares in Q2 2026, an estimated $391.
  • NeuroSense Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #4234 holding.
  • Creative Planning first reported a position in NeuroSense Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Creative Planning's NeuroSense Therapeutics position peaked at $9.16K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.